Ova1 test a bio-marker blood test to determine if ovarian masses are cancerous or benign was approved by the FDA on March 9, 2010. The test developed by Vermillion, Inc uses five biomarkers combined in one test. It is available through Quest Diagnostics. The test should be use in conjunction with regular physician exams and radiological tests.
Quest Press Release
Vermillion, Inc Site
Although Ova1 in a study at 27 hospitals found 92% of the cancers versus 72 found by normal methods there were also a number of false positives.
Every Day is a Blessing!